TARS Q4 2025 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$152M+128.4% YoY

Gross Profit

$141M92.8% margin

Operating Income

-$8M-5.3% margin

Net Income

-$8M-5.5% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+27.8%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$13M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$562M

Total Liabilities

$219M

Stockholders' Equity

$343M

Cash & Equivalents

$184M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$152M	$66M	+128.4%
Gross Profit	$141M	$61M	+128.9%
Operating Income	-$8M	-$24M	+67.3%
Net Income	-$8M	-$23M	+63.8%

Revenue Segments

Product

$152M100%